ACS and Melanoma Research Alliance to fund pilot research projects

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A new partnership between the American Cancer Society and the Melanoma Research Alliance will fund research aimed at decreasing side effects associated with checkpoint inhibitors in hopes of increasing further cancer immunotherapy benefits. FDA has approved use of checkpoint drugs to combat seven cancer types including lung, head and neck, kidney cancer, bladder cancer, Merkel...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login